Меню
Идёт набор NCT07031531

Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease

Без фазы С лечением Premature Coronary Heart Disease

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: AI-Enabled Stratified Management System, Usual Post-Discharge Care.
Кому может быть актуально
Состояния в реестре: Premature Coronary Heart Disease. Базовые параметры: 18 лет — 45 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease (SMART-CHD): A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Обзор

The goal of this clinical trial is to learn if an AI-enabled stratified management system (SMART-CHD) can improve post-discharge outcomes in adults aged 18-45 with premature coronary artery disease. The main questions it aims to answer are: 1. Does SMART-CHD reduce the combined rate of all-cause death, myocardial infarction, stroke and rehospitalization within 12 months? 2. Does SMART-CHD achieve better control of modifiable risk factors compared with usual care? Researchers will compare SMART-CHD to standard discharge management (verbal and printed instructions on medications, follow-up timelines and lifestyle advice) to see if the AI-driven platform leads to fewer adverse events and improved risk-factor profiles. Participants will: 1. Install and use the SMART-CHD mobile app after a 10-minute structured orientation session with supervised simulations. 2. Complete regular in-app surveys on lifestyle behaviors, laboratory/imaging results and clinical events (with OCR-powered LLM assistance). 3. Wear paired sensors for continuous monitoring of blood pressure, heart rate and other physiologic metrics. 4. Receive automated EHR data harvesting, AI-driven voice-call reminders, and real-time CRC support via a dedicated WeChat group. 5. Follow personalized, guideline-based risk-factor recommendations (diet, exercise, sleep, weight, smoking, alcohol, hypertension, dyslipidemia, diabetes).

Вмешательства

  • Комбинированный продукт AI-Enabled Stratified Management System
    After discharge, participants install SMART-CHD, sync their EHR data, and complete a 10-minute orientation. They then use the app's OCR-assisted surveys to report lifestyle, lab, and event data, while paired wearables stream continuous vitals. AI voice calls and a CRC-managed WeChat group deliver reminders and support. The app's embedded predictive models stratify them into risk tiers and generate tier-specific follow-up schedules. Personalized lifestyle modification guidance, dietary plans, and
  • Комбинированный продукт Usual Post-Discharge Care
    Usual discharge protocol comprising verbal and printed discharge instructions addressing medication schedules, follow-up timelines, and lifestyle optimization strategies.

Первичные конечные точки

  • Cardiovascular Composite Endpoint Events [Срок оценки: Assessed at 12 months post-discharge]
Вторичные конечные точки (8)
  • Individual components of cardiac events [Срок оценки: Assessed at 12 months post-discharge]
  • LDL-C level [Срок оценки: Assessed at 12 months post-discharge]
  • LDL-C Goal Attainment [Срок оценки: Assessed at 12 months post-discharge]
  • Blood pressure level [Срок оценки: Assessed at 12 months post-discharge]
  • Blood pressure goal attainment [Срок оценки: Assessed at 12 months post-discharge]
  • Hemoglobin A1c level [Срок оценки: Assessed at 12 months post-discharge]
  • Smoking [Срок оценки: Assessed at 12 months post-discharge]
  • Medication adherence to antiplatelet agents and statins [Срок оценки: Assessed at 12 months post-discharge]

Критерии участия

Критерии включения

  • Patients with coronary heart disease aged 18-45 years;
  • The patient or a close family member is capable of using a smartphone and mobile application (App);
  • Willing to participate in the study and able to provide written informed consent.

Критерии исключения

  • Severe cognitive impairment;
  • Advanced-stage malignancy;
  • Life expectancy less than 12 months;
  • Severe multi-organ failure;
  • Refusal to provide written informed consent.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Профилактика

Центры проведения

Китай · 16 центров
  • The First Affiliated Hospital of University of Science and Technology of China — Хэфэй
  • Fuwai Hospital, Chinese Academy of Medical Sciences/National Center for Cardiovascular Dis — Пекин
  • Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen — Шэньчжэнь
  • The First Hospital of Hebei Medical University — Shijiazhuang
  • The Second Hospital Of Hebe Medical University — Shijiazhuang
  • The First Affiliated Hospital of Henan University of Science and Technology — Luoyang
  • Henan Provincial Chest Hospital — Чжэнчжоу
  • Zhengzhou University Affiliated Zhengzhou Central Hospital — Чжэнчжоу
  • … и ещё 8 центров

Идентификаторы

NCT: NCT07031531 · 2023ZD0504005

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗